Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
Our providers take a holistic approach to reproductive health and metabolic wellness, recognizing that hormonal health, weight, and overall wellbeing are interconnected
Compounded peptides are sometimes offered when branded medications are expensive or in short supply, but the FDA has warned that compounded semaglutide and tirzepatide may not meet the same safety or quality standards as FDA-approved products (FDA statement on compounded semaglutide)
7.5 A Phase II Study of Liraglutide (Victoza , Saxenda ) in PD A randomized, double-blind, placebo-controlled phase II clinical trial suggested that liraglutide has protective effects in patients with PD (NCT02953665)